Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143492 · ClinicalTrials.gov registry record
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
A clinical trial, sponsored by Argos Therapeutics.
- Completed
- Registry status
- 11
- Enrollment target
NCT02143492: Completed study, sponsored by Argos Therapeutics.
NCT02143492 is a clinical trial that has completed, run by Argos Therapeutics. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02143492 has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
Standard treatment for kidney cancer is to remove the tumors from the body with surgery. The purpose of this clinical trial is to collect, preserve, and store excess kidney cancer tumor specimens that would normally be discarded after surgery.
Primary Outcome
Tumor specimen collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-07 |
What the finished NCT02143492 record still lists
NCT02143492 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02143492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02143492 about?
NCT02143492 is a clinical study titled "Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC". Standard treatment for kidney cancer is to remove the tumors from the body with surgery. The purpose of this clinical trial is to collect, preserve, and store excess kidney cancer tumor specimens that would normally be discarded after surgery.
What is the current status of trial NCT02143492?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2013-08. Estimated completion is 2015-07.
Who is sponsoring clinical trial NCT02143492?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia